Viking Therapeutics Balance Sheet Health
Financial Health criteria checks 6/6
Viking Therapeutics has a total shareholder equity of $911.4M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $937.9M and $26.4M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$930.44m |
| Equity | US$911.45m |
| Total liabilities | US$26.44m |
| Total assets | US$937.89m |
Recent financial health updates
Companies Like Viking Therapeutics (NASDAQ:VKTX) Can Afford To Invest In Growth
Sep 07
We Think Viking Therapeutics (NASDAQ:VKTX) Can Easily Afford To Drive Business Growth
Apr 26We're Hopeful That Viking Therapeutics (NASDAQ:VKTX) Will Use Its Cash Wisely
Jan 09We're Not Very Worried About Viking Therapeutics' (NASDAQ:VKTX) Cash Burn Rate
Sep 21Viking Therapeutics (NASDAQ:VKTX) Is In A Good Position To Deliver On Growth Plans
Jun 07We're Not Very Worried About Viking Therapeutics' (NASDAQ:VKTX) Cash Burn Rate
Mar 05Recent updates
Viking Therapeutics: Too Much Excitement Around Oral VK2735, Even If It Met High Expectations
Nov 04Viking Therapeutics: Lots Of Positives
Oct 28Viking Therapeutics: Market Rightly Excited By GLP-1 Promise -- A Buy Ahead Of Data
Sep 25Companies Like Viking Therapeutics (NASDAQ:VKTX) Can Afford To Invest In Growth
Sep 07Viking Therapeutics: GLP-1/GIP Receptor Agonist And Its Competitive Landscape
Aug 30Viking Therapeutics: Better-Than-Expected Trial Timelines While Pipeline Expands
Jul 25We Think Viking Therapeutics (NASDAQ:VKTX) Can Easily Afford To Drive Business Growth
Apr 26Viking Therapeutics: Future Weight Loss Heavyweight?
Apr 02We're Hopeful That Viking Therapeutics (NASDAQ:VKTX) Will Use Its Cash Wisely
Jan 09We're Not Very Worried About Viking Therapeutics' (NASDAQ:VKTX) Cash Burn Rate
Sep 21Viking Therapeutics (NASDAQ:VKTX) Is In A Good Position To Deliver On Growth Plans
Jun 07We're Not Very Worried About Viking Therapeutics' (NASDAQ:VKTX) Cash Burn Rate
Mar 05Viking Therapeutics: Playing Second Fiddle To Madrigal
Aug 30We Think Viking Therapeutics (NASDAQ:VKTX) Can Afford To Drive Business Growth
Jul 13Revisiting Viking Therapeutics
Apr 20We Think Viking Therapeutics (NASDAQ:VKTX) Can Afford To Drive Business Growth
Apr 12We Think Viking Therapeutics (NASDAQ:VKTX) Can Afford To Drive Business Growth
Dec 17Viking Therapeutics: Remaining Bullish And Sticking To My Plan
Aug 27Viking Therapeutics soars 11% on encouraging VK0214 data in rare metabolic disorder
Jun 17Have Insiders Been Selling Viking Therapeutics, Inc. (NASDAQ:VKTX) Shares This Year?
Jan 13Viking Therapeutics announces senior management appointments
Jan 06Do Institutions Own Viking Therapeutics, Inc. (NASDAQ:VKTX) Shares?
Dec 09
Viking Therapeutics: Progressing Steadily, But Concerns Remain
Nov 29Financial Position Analysis
Short Term Liabilities: VKTX's short term assets ($936.6M) exceed its short term liabilities ($25.7M).
Long Term Liabilities: VKTX's short term assets ($936.6M) exceed its long term liabilities ($755.0K).
Debt to Equity History and Analysis
Debt Level: VKTX is debt free.
Reducing Debt: VKTX had no debt 5 years ago.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: VKTX has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: VKTX has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 25% each year